{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:27:10Z","timestamp":1770773230172,"version":"3.50.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Neoadjuvant chemotherapy (NAC) is currently widely indicated for treatment of breast cancer (BC), due to several advantages that include early introduction of systemic therapy, determine drug's efficacy, potential to reduce both the tumor volume of the primary tumor and\u00a0regional lymph nodes, reduction in the extent of surgery in the breast and axilla, evaluation of the pathological response, and rescue therapies in specific cases. Several studies have demonstrated better long\u2010term outcomes among patients who achieve pathologic complete response (pCR) than those with residual tumor (non\u2010pCR). The association between pCR and long\u2010term outcomes is strongest among HER2+ and triple\u2010negative breast cancer (TNBC). Therefore, evaluating the efficacy of chemotherapy in real time is an important issue.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between 2016 and 2018, a cohort carried out of 37 patients with locally advanced BC: 21 women with TNBC and 16 HER2+ submitted to NAC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>High levels of sPD1 and sFas in the plasma of TNBC and HER2 patients compared to the controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Low levels of sPDL1 in HER2+ patients with pCR compared to non\u2010pCR (<jats:italic>p<\/jats:italic>\u2009=\u20090.021). In paired analysis, statistical differences of sFasL levels in TNBC and HER2+ patients before and after NAC (<jats:italic>p<\/jats:italic>\u2009=\u20090.0065 and <jats:italic>p<\/jats:italic>\u2009=\u20090.041, respectively), and in sFAS levels in HER2+ patients before and after NAC (<jats:italic>p<\/jats:italic>\u2009=\u20090.0071).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present study suggests that soluble sFas, sFasL, sPD1, and sPDL1 levels were apoptosis\u2010related markers with potential predictive value of response to neoadjuvant chemotherapy in patients with TNBC and HER2+ breast cancer.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.27723","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:58:41Z","timestamp":1748912321000},"page":"817-824","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Soluble sFas, sFasL, sPD1, and sPDL1 Analyses in the Peripheral Blood of Locally Advanced Breast Cancer Patients Before and After Neoadjuvant Chemotherapy"],"prefix":"10.1002","volume":"132","author":[{"given":"Carolina de Souza","family":"Vasconcelos","sequence":"first","affiliation":[{"name":"Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) Recife Brazil"},{"name":"Sociedade Pernambucana de Combate ao Cancer, Hospital de C\u00e2ncer de Pernambuco (HCP) Recife Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Ramos Tejo","family":"Salgado","sequence":"additional","affiliation":[{"name":"Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) Recife Brazil"},{"name":"Sociedade Pernambucana de Combate ao Cancer, Hospital de C\u00e2ncer de Pernambuco (HCP) Recife Brazil"},{"name":"International Research Center, A.C. Camargo Cancer Center S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-8210","authenticated-orcid":false,"given":"Mario Rino","family":"Martins","sequence":"additional","affiliation":[{"name":"Sociedade Pernambucana de Combate ao Cancer, Hospital de C\u00e2ncer de Pernambuco (HCP) Recife Brazil"},{"name":"International Research Center, A.C. Camargo Cancer Center S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo Caiado","family":"Anuncia\u00e7\u00e3o","sequence":"additional","affiliation":[{"name":"Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) Recife Brazil"},{"name":"Sociedade Pernambucana de Combate ao Cancer, Hospital de C\u00e2ncer de Pernambuco (HCP) Recife Brazil"},{"name":"International Research Center, A.C. Camargo Cancer Center S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise Viana","family":"Sobral","sequence":"additional","affiliation":[{"name":"Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) Recife Brazil"},{"name":"Sociedade Pernambucana de Combate ao Cancer, Hospital de C\u00e2ncer de Pernambuco (HCP) Recife Brazil"},{"name":"International Research Center, A.C. Camargo Cancer Center S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leuridan Cavalcante","family":"Torres","sequence":"additional","affiliation":[{"name":"Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) Recife Brazil"},{"name":"Sociedade Pernambucana de Combate ao Cancer, Hospital de C\u00e2ncer de Pernambuco (HCP) Recife Brazil"},{"name":"Department of Medicine, Escola Paulista de Medicina Universidade Federal de S\u00e3o Paulo S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-17-0627"},{"key":"e_1_2_9_4_1","unstructured":"M.deOliveira SantosEstimativa\/2020 \u2013 Incid\u00eancia de C\u00e2ncer no Brasil. Rev. Bras. Cancerol. [Internet]. 20\u00b0 de mar\u00e7o de 2020 [citado 10\u00b0 de fevereiro de 2022]66 (1):e\u201000927. Dispon\u00edvel em:https:\/\/rbc.inca.gov.br\/revista\/index.php\/revista\/article\/view\/927."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"e_1_2_9_7_1","first-page":"1313","volume-title":"J Cell Physiol","author":"Dermani F. K.","year":"2019"},{"issue":"05","key":"e_1_2_9_8_1","first-page":"378","article-title":"Significance of Serum Soluble Fas Ligand in Patients With Bladder Carcinoma","volume":"30","author":"Jia Quan\u2010an","year":"2003","journal-title":"China Research on Prevention and Treatment"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3636"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1310358"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3216"},{"issue":"1","key":"e_1_2_9_12_1","first-page":"52","article-title":"Neoadjuvant Chemotherapy Considerations in Triple\u2010Negative Breast Cancer","volume":"7","author":"McAndrew N.","year":"2018","journal-title":"Journal of Targeted Therapies in Cancer"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-002-6378-5"},{"issue":"3","key":"e_1_2_9_14_1","first-page":"2387","article-title":"Variations of Soluble Fas and Cytokeratin 18\u2010Asp 396 Neo\u2010Epitope in Different Cancers During Chemotherapy","volume":"26","author":"Pichon M. F.","year":"2006","journal-title":"Anticancer Research"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7510905"},{"issue":"5","key":"e_1_2_9_16_1","first-page":"2047","article-title":"Apoptosis\u2010Related Biomarkers sFAS, MIF, ICAM\u20101 and PAI\u20101 in Serum of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","volume":"32","author":"Fersching D. M.","year":"2012","journal-title":"Anticancer Research"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.08.012"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1296-1361"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.06.004"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587460"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00262-021-02898-4"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009617"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17546"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919848872"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1561120"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.08.009"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2271-4"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.03.008"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.04.014"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-07112-x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0329"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.311"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.27723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:40:53Z","timestamp":1759830053000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.27723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/jso.27723"],"URL":"https:\/\/doi.org\/10.1002\/jso.27723","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"2024-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}